Synta’s Ganetespib Could Break The Hsp90i Curse

 
• By Shirley Haley

If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.

CHICAGO – Synta Pharmaceuticals Corp.’s second-generation heat shock protein 90 (Hsp 90) inhibitor ganetespib may provide the first successful proof of principle for the class and the first drug in a decade to improve outcomes in the salvage setting for advanced lung cancer.

Top-line results for the Phase II GALAXY-I trial in patients with stage IV adenocarcinoma of the lung were reported at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

Global Guideline Signals ‘Paradigm Shift’ For Pregnant And Breastfeeding Women, Says EMA

 
• By Anabel Costa-Ferreira

The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.

More from R&D